Your browser doesn't support javascript.
loading
Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement.
Treibel, Thomas A; Fontana, Marianna; Gilbertson, Janet A; Castelletti, Silvia; White, Steven K; Scully, Paul R; Roberts, Neil; Hutt, David F; Rowczenio, Dorota M; Whelan, Carol J; Ashworth, Michael A; Gillmore, Julian D; Hawkins, Philip N; Moon, James C.
Afiliação
  • Treibel TA; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Fontana M; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Gilbertson JA; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Castelletti S; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • White SK; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Scully PR; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Roberts N; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Hutt DF; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Rowczenio DM; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Whelan CJ; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Ashworth MA; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Gillmore JD; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Hawkins PN; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
  • Moon JC; From the Cardiovascular Magnetic Resonance Imaging Unit, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom (T.A.T., M.F., S.C., S.K.W., P.R.S., N.R., J.C.M.); Institute of Cardiovascular Science (T.A.T., M.F., S.K.W., J.C.M.) and National Amyloidosis Centre, Royal Free Campus (M.
Article em En | MEDLINE | ID: mdl-27511979
ABSTRACT

BACKGROUND:

Calcific aortic stenosis (cAS) affects 3% of individuals aged >75 years, leading to heart failure and death unless the valve is replaced. Wild-type transthyretin cardiac amyloid is also a disorder of ageing individuals. Prevalence and clinical significance of dual pathology are unknown. This study explored the prevalence of wild-type transthyretin amyloid in cAS by myocardial biopsy, its imaging phenotype and prognostic significance. METHODS AND

RESULTS:

A total of 146 patients with severe AS requiring surgical valve replacement underwent cardiovascular magnetic resonance and intraoperative biopsies; 112 had cAS (75±6 years; 57% men). Amyloid was sought histologically using Congo red staining and then typed using immunohistochemistry and mass spectrometry; patients with amyloid underwent clinical evaluation including genotyping and (99m)TC-3,3-diphosphono-1,2-propanodicarboxylic-acid (DPD) bone scintigraphy. Amyloid was identified in 6 of 146 patients, all with cAS and >65 years (prevalence 5.6% in cAS >65). All 6 patients had wild-type transthyretin amyloid (mean age 75 years; range, 69-85; 4 men), not suspected on echocardiography. Cardiovascular magnetic resonance findings were of definite cardiac amyloidosis in 2, but could be explained solely by AS in the other 4. Postoperative DPD scans demonstrated cardiac localization in all 4 patients who had this investigation (2 died prior). At follow-up (median, 2.3 years), 50% with amyloid had died (versus 7.5% in cAS; 6.9% in age >65 years). In univariable analyses, the presence of transthyretin amyloidosis amyloid had the highest hazard ratio for death (9.5 [95% confidence interval, 2.5-35.8]; P=0.001).

CONCLUSIONS:

Occult wild-type transthyretin cardiac amyloid had a prevalence of 6% among patients with AS aged >65 years undergoing surgical aortic valve replacement and was associated with a poor outcome.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Valva Aórtica / Estenose da Valva Aórtica / Implante de Prótese de Valva Cardíaca / Neuropatias Amiloides Familiares / Cardiomiopatias Tipo de estudo: Etiology_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Valva Aórtica / Estenose da Valva Aórtica / Implante de Prótese de Valva Cardíaca / Neuropatias Amiloides Familiares / Cardiomiopatias Tipo de estudo: Etiology_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article